Replies to post #32233 on Ariad Pharmaceuticals Inc fka ARIA

[jaybe]

Changes to '113 trial...added 5th Cohort for brain mets...

Trial size increased from 130 to 175.

Narrowed cohort #3 to EGFR with T790M.

Added new cohort #5: NSCLC patients whose tumors exhibit ALK rearrangements and who have active, measurable brain metastases:
-Either crizotinib naive or resistant;
-Have at least one measurable brain lesion
-Previously untreated brain metastases with radiologically documented new or progressing brain lesions.


Sounds like 1st line ALK with brain mets to me.